Tradestie Institutional Equity Comparison Engine

NVCT vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin while NVCT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, NVCT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, NVCT sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
NVCT N/M vs MNOV 8.5x Fwd P/E
Growth & Margin Winner MNOV
Op Margin 0.0% vs -1232.2% ยท YoY +0.0% vs +12.4%
Momentum & Technical Winner NVCT
1Y +224.8% vs -8.4% ยท 52W Pos 58% vs 3%
Options & Structure Winner NVCT
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (50th %ile IV)
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.39
-2.27% 1D
Market Cap $682.3M
1M Return -7.18%
1Y Return +224.79%
Forward P/E N/M
Unified AI Score
48.4 / 100 HOLD
Tech 34.0 Fund 49.0 Flow 67.0 Mom 50.0
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVCT +224.79% MNOV -8.39% Spread: +233.18 pp (NVCT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVCT TTM Op. Margin: 0.0% MNOV TTM Op. Margin: -1232.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs MNOV. Trailing 12-month operating profitability (NVCT 0.0% vs MNOV -1232.2%) and valuation multiples (NVCT N/M vs MNOV 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVCT (3) vs MNOV (6)
Institutional Metric NVCT MNOV Criterion Row Winner
Market Capitalization Scale $682.3M $65.1M Larger Scale NVCT
Trailing P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY) Growth +0.0% +12.4% Higher Growth MNOV
Operating Margin (TTM) Profitability 0.0% -1232.2% Higher Margin NVCT
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -67.0% -24.8% Higher ROE MNOV
52-Week Range Position Momentum 58% ($6โ€“$29) 3% ($1โ€“$4) Stronger Trend NVCT
Beta / 30D Volatility Risk Regime 0.71ฮฒ ยท 80% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 48.4 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVCT vs MNOV Buy Guide
NVCT BREAKDOWN
102d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live NVCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVCT nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.